Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC) Meeting Abstract
| Authors: | Garrido-Laguna, I.; Wolpin, B. M.; Park, W.; Azad, N. S.; Spira, A. I.; Starodub, A.; Sommerhalder, D.; Punekar, S. R.; Herzberg, B.; Barve, M. A.; Pelster, M.; Valerin, J. B.; Hecht, J. R.; Vora, R.; Hegde, A. M.; Gustafson, C.; Tao, L.; Kar, S.; Lin, K. K.; Hong, D. S. |
| Abstract Title: | Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC) |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.722 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 722 -- Source: CINAHL Plus with Full Text |
